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Preeclampsia is a hypertensive disorder of pregnancy asso-ciated with substantive maternal and perinatal mortality 
and morbidity.1 There is currently no curative treatment for 
preeclampsia, and only childbirth and delivery of the placenta 
alleviate maternal symptoms. The development of therapeutic 
strategies for preeclampsia is one of the highest priorities in 
perinatal medicine.
During preeclampsia, a massive amount of a sVEGFR1 
(soluble form of the vascular endothelial growth factor re-
ceptor 1), also named sFlt-1, is released by the placenta into 
the maternal circulation, resulting in inhibition of the proan-
giogenic effects of its ligands, VEGF (vascular endothelial 
growth factor)-A, and PlGF (placental growth factor) on the 
maternal endothelium.2 These angiogenic factors are essential 
for the survival of endothelium, thus explaining the endothe-
lial dysfunction during preeclampsia.3,4
On the basis of compelling evidence that circulating sFlt-1 
is a critical and potentially rate-limiting step in the pathobiol-
ogy of preeclampsia, it is supposed that by reducing its circu-
lating concentrations with an extracorporeal device the disease 
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Abstract—Preeclampsia is a hypertensive pregnancy disease associated with a massive increase in sFlt-1 (soluble form 
of the vascular endothelial growth factor 1) in the maternal circulation, responsible for angiogenic imbalance and 
endothelial dysfunction. Pilot studies suggest that extracorporeal apheresis may reduce circulating sFlt-1 and prolong 
pregnancy. Nonspecific apheresis systems have potential adverse effects because of the capture of many other molecules. 
Our concept is based on a specific and competitive apheresis approach using VEGF (vascular endothelial growth factor) 
functionalized magnetic beads to capture sFlt-1 while releasing endogenous PlGF (placental growth factor) to restore a 
physiological angiogenic balance. Magnetic beads were functionalized with VEGF to capture sFlt-1. Experiments were 
performed using PBS, conditioned media from human trophoblastic cells, and human plasma. The proof of concept was 
validated in dynamic conditions in a microfluidic device as an approach mimicking real apheresis. Magnetic beads were 
functionalized with VEGF and characterized to evaluate their surface ligand density and recognition capabilities. VEGF-
coated magnetic beads proved to be an efficient support in capturing sFlt-1 and releasing PlGF. In static conditions, sFlt-1 
concentration decreased by 33±13%, whereas PlGF concentration increased by 27±10%. In dynamic conditions, the 
performances were improved, with 40% reduction of sFlt-1 and up to 2-fold increase of free PlGF. The sFlt-1/PlGF ratio 
was reduced by 63% in the plasma of preeclamptic patients. Apheresis was also associated with VEGF release. A ligand-
based approach using VEGF-coated beads is an effective approach to the capture of sFlt-1 and the release of endogenous 
PlGF. It offers new perspectives for the treatment of preeclampsia.  (Hypertension. 2019;74:145-153. DOI: 10.1161/
HYPERTENSIONAHA.118.12380.) • Online Data Supplement
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progression could be limited. Based on the positive charge of 
sFlt-1, dextran sulfate columns have been used to remove ex-
cess circulating maternal sFlt-1 during preeclampsia.5 Thadhani 
et al6 have shown that this nonspecific method of apheresis for 
women with preterm preeclampsia can reduce sFlt-1 concen-
trations by 18%. A proof-of-concept trial on selective removal 
of sFlt-1 in healthy volunteers and preeclamptic women using 
an sFlt-1 antibody-specific adsorption column is ongoing to 
test the safety and efficacy of this procedure.7
The objective of this study was to develop and provide 
the proof of concept of a selective and competitive apheresis 
approach to reduce circulating sFlt-1 while increasing free PlGF 
to restore the physiological angiogenic balance in the maternal 
circulation. To shift the equilibrium of sFlt-1/PlGF binding, we 
grafted magnetic beads with ligands of sFlt-1 which competes 
with PlGF. To increase sFlt-1 capture and optimize equilibrium 
displacement, we chose to use VEGF as a competitive ligand, 
which has a >10× greater affinity for sFlt-1 than does PlGF.8 
This competitive biomimetic binding approach captures circu-
lating sFlt-1 while releasing endogenous PlGF, thereby increas-
ing the bioavailability of PlGF and potentiating its proangiogenic 
effects on maternal endothelial function. To go one step further 
in validating the potential of our approach, it was integrated in a 
microfluidic device mimicking a miniaturized extracorporeal cir-
culation system (Figure S1 in the online-only Data Supplement).
Material and Methods
Data that support the findings of this study are available from the cor-
responding author on reasonable request. Magnetic beads Dynabeads 
M-280 streptavidin, magnetic support Dynal Dynabeads MPC-
DynaMag-96 Side Skirted Magnet, and DynaMag-5 Magnet were 
from Invitrogen. BSA fraction IV (BSA) and PBS without Ca2+ and 
Mg2+ were from Eurobio. Tween 20 was from Sigma-Aldrich. Human 
recombinant sFlt-1 with an antibody constant fraction (rhVEGFR1/
Fc Chimera, Ser27-His687) and human recombinant PlGF (rh PlGF) 
were from R&D Systems. Kits from R&D systems (Quantikine) or 
from Roche Diagnostics (Elecsys) were used for the assay of free 
VEGF, free PlGF, sFlt-1, and sVEGFR-2 (soluble form of the vas-
cular endothelial growth factor receptor 2).
Bead Functionalization and Characterization
Dynabeads M-280 streptavidin were functionalized with homemade 
bt-VEGF (biotinylated VEGF, see online-only Data Supplement for 
VEGF95-AVI-biotin expression and purification, AVI being a C-terminus 
tag sequence of 15 amino acids) or with human anti–Flt-1 biotinylated 
antibody (R&D Systems). The functionalization was performed follow-
ing the supplier’s information with slight modifications (see SI).
After bead functionalization, 2 tests were performed for their 
characterization: one to assess the ligand surface density and the 
other to ensure the ability of the grafted ligand to bind sFlt-1 (see SI).
Proof of Concept With Recombinant Protein
Formation and Assay of sFlt-1/PlGF Complexes
Increasing concentrations of rhVEGFR1/Fc (from 0 to 1000 ng/mL) 
in PBS/0.1% BSA were added to the same volume of a solution at 4 
ng/mL of rhPlGF in PBS/0.1% BSA and the mixture was incubated 
for 1 hour at 37°C. Complex formation was quantified after assay of 
free rhPlGF with Quantikine kits. The maximum absorbance signal 
(S
max
) was given by the solution of rhPlGF without rhVEGFR1/Fc. 
The amounts of free and complexed rhPlGF were obtained using 
equations 1 and 2:
%rhPlGF S
Sfree
max
= ×100
 (1)
%rhPlGF S S
Scomplexed
max
max
=
−
×100 (2)
Capture of rhVEGFR1/Fc and Release of rhPlGF With 
VEGF-Beads
Two hundred microliters of the solution of rhVEGFR1/Fc/rhPlGF 
complexes (see Formation and Assay of sFlt-1/PlGF Complexes) 
was incubated in a tube with 5 µL (50 µg) of VEGF-coated beads 
(V-beads) at 105 pmol of bt-VEGF/mg beads. For the negative con-
trol, nonfunctionalized beads (C-beads) were used. After 1-hour in-
cubation at 37°C with stirring, the concentrations of free rhPlGF and 
rhVEGFR1/Fc were measured with Quantikine kits.
Ethical Statements and Biological Samples
The local ethics committee (Comité de Protection des Personnes Ile 
de France 3) approved the studies of cultures of human primary cells 
from placenta tissue (Perinat Collection ANR-10-EQPX-0010) and the 
human plasma sample from the Angiogenic switch to Physiological 
state by Extracorporeal Removal of sFlt1 and release of free PlGF case/
control prospective study (http://www.clinicaltrials.gov. Unique identi-
fier: NCT03188900). All patients gave written consent for participation 
in these studies. For the primary cell culture, cytotrophoblasts were iso-
lated as previously described, 9and the conditioned media (CM) were 
collected after 72 hours of culture and then stored at −80°C.
Microfluidic Experiments
The characteristics and procedures for the chip fabrication and the 
microfluidic set-up were previously described and are summarized in 
the SI.10 PBS containing 1% BSA (Sigma-Aldrich) was used for the 
conditioning of the chip.
Sample Treatment
The chip and tubing system was initially filled with washing buffer, 
and the temperature was adjusted to 37°C using an indium tin 
oxide glass slide with feedback regulation from a voltage controller 
(Eurotherm 3508) via a thermocouple gauge installed inside a slot 
in the polydimethylsiloxane chip. When using plasma samples, pre-
liminary 3-minute spin centrifugation was used to remove any solid 
aggregates, and only supernatant was then collected.
The sample (150 µL) flow in the chip chamber was 1 µL/min. 
A Tygon tube (Saint Gobain AAD04103 Tygon Non-DEHP Medical 
Microbore Tubing, 0.020” ID, 0.060” OD) connected at the outlet 
was used to collect the emerging solution.
Results
Functionalization and Characterization of 
Streptavidin Magnetic Beads
Functionalization
To study the impact of VEGF density on the capacity of the 
beads to bind sFlt-1, it was necessary to estimate precisely the 
surface saturation of the magnetic beads because steric hin-
drance, repulsion, or interactions may play a role in protein 
recognition.11,12 Based on previous work,13 4 different grafted 
V-beads with ligand densities between 11.7·103 and 158·103 
VEGF/µm2 were prepared by changing the initial quantity of 
VEGF, and then characterized (Table S1).
Binding of sFlt-1
To evaluate how the VEGF grafted on the beads was still able 
to recognize human recombinant sFlt-1 with good affinity, 
a binding assay was developed that yielded the dissociation 
constant of the immobilized VEGF/rhVEGFR1/Fc complex 
(Figure S2). The binding assay was performed with the 35% 
saturated beads (105 pmol VEGF/mg of beads) and revealed 
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a Kd value of 1.0±0.4 nmol/L (n=5). This value is in good 
agreement with the value obtained when VEGF is coated in a 
plate for a classical ELISA test14 and confirms the high ligand-
receptor affinity.
Proof of Concept
Capture and Release of Recombinant Proteins
The ability of V-beads simultaneously to capture sFlt-1 and 
release PlGF was first demonstrated in static conditions with 
recombinant proteins.
Formation of rhVEGFR1/Fc /rhPlGF Complexes
The first step was to produce artificial samples of varying com-
positions of complexed and free proteins. To do so, it was nec-
essary to control the formation of recombinant rhVEGFR1/Fc/
rhPlGF complexes (Figure 1A). To estimate the initial amount 
of each protein required to form the complex, a theoretical 
study was performed (see SI). Taking into account these cal-
culations, the initial concentration of rhPlGF was kept con-
stant at 6.9 pmol/L, and the selected initial rhVEGFR1/Fc 
concentrations ranged from 0 to 500 pmol/L. The estimated 
Kd value for the rhPlGF/rhVEGFR1/Fc complex was 22±3 
pmol/L (n=3; Figure S3).
sFlt-1 Capture and PlGF Release
The second step of the proof of concept was to evaluate 
the ability of V-beads to capture rhsFlt-1 and to disrupt the 
rhVEGFR1/Fc/rhPlGF complex (Figure 1A). Thus, 3 dif-
ferent complex solutions (C1, C2, and C3) obtained from 3 
different initial concentrations of rhVEGFR1/Fc (ranging 
from 52.3 to 29.2 pmol/L), were incubated with C-beads as 
the negative control and V-beads. The final concentrations 
of rhVEGFR1/Fc and rhPlGF were thus determined in the 
supernatants. Figure 1B and 1C show the molar quantity of 
total rhVEGFR1/Fc and free rhPlGF in each solution before 
(sample bar) and after incubation (C- and V-beads bars). No 
significant effects were observed when C-beads were used, 
showing that the nonspecific interactions were minimized. In 
contrast, a significant decrease in rhVEGFR1/Fc concentra-
tion accompanied by an increase of PlGF concentration in the 
presence of V-beads was observed in all the samples tested. 
In addition, because the total amount of rhPlGF used to form 
the complexes is known (6.9 pmol/L), the % of PlGF initially 
and finally complexed could be calculated. Although around 
90% of initial rhVEGFR1/Fc was captured, only 20% of in-
itial rhPlGF complexed to rhVEGFR1/Fc was released. This 
could be explained by the great difference in the amounts of 
proteins used to form the complexes (Table S2). Note that, in 
this study, we chose conditions where almost all the rhPlGF 
was complexed (>90%) and rhVEGFR1/Fc was in high ex-
cess, which is the case during severe preeclampsia.
These results with recombinant proteins demonstrate our 
competitive approach for the capture of sFlt-1 and the release 
of PlGF and allow us to move on to more complex media to 
validate the strategy.
Impact of the Saturation Rate on the Capture 
of sFlt-1 and Release of PlGF
The efficiency of sFlt-1 capture and PlGF release was assessed 
according to the surface ligand density of the V-beads. The 
amount of bt-VEGF coated on streptavidin Dynabeads was 
evaluated from 30 to 259 pmol/mg of beads corresponding 
to a surface ligand density ranging from 11.7·103 to 102·103 
VEGF/µm2 (Table S1). To investigate how our system was able 
to accommodate complex samples, these experiments were 
performed with CM obtained from human trophoblastic pri-
mary cells in which the initial concentrations of sFlt-1total and 
PlGFfree were 0.27 pmol/mL (20868 pg/mL) and 0.015 pmol/
mL (292 pg/mL), respectively. Two hundred microliters of this 
CM was incubated with the necessary amount of beads to en-
sure the required VEGF excess compared with initial sFlt-1 in 
the sample. The amount of sFlt-1 captured increased when the 
ligand surface density decreased, from 30% capture at 100·103 
VEGF/µm2 to 60% capture at 12·103 VEGF/µm2 for the case 
of a 500 molar excess of VEGF (Figure 2A). This could be 
explained by a high steric hindrance at higher saturation rate 
limiting the capture.12 Then, at constant surface ligand density, 
the effect of VEGF in excess compared with the initial concen-
tration of sFlt-1 was evaluated. We increased the mass of beads 
to obtain a 10 to 500 molar excess of VEGF. As expected, the 
capture increased with the excess of VEGF. However, over 
100 molar excess only a slight improvement of capture was 
observed. For PlGF release, the excess VEGF plays a more im-
portant role than for sFlt-1 because this molecule is initially 
complexed to sFlt-1 and has to be displaced. In addition, the 
levels of PlGF are considerably lower than those of sFlt-1 
(sometimes ≥1 order of magnitude). For example, in the CM 
used for this study, the initial quantity of free PlGF in solution 
was 3 fmol, whereas the total quantity of sFlt-1 was 54 fmol, 
corroborating the great difference in concentration between the 
2 molecules and the fact that most of the PlGF will be com-
plexed. Thus, we can observe in Figure 2B how a molar excess 
of at least 100 is required to have a significant release of PlGF.
Based on these series of experiments, the selected sur-
face ligand density for further experiments was fixed at 41·103 
VEGF/µm2 (105 pmol VEGF/mg of beads; 35% saturation 
rate) as the better compromise in terms of beads and VEGF 
consumption and performance of capture/release. In patient 
samples, the quantities of these factors vary considerably and 
consequently the VEGF excess from beads may affect the effi-
ciency of apheresis differently. Nevertheless, previous experi-
ments show that this efficiency is not negatively affected if we 
ensure at least a 100 molar excess (VEGF/sFlt-1).
Valorization of the Competitive Strategy
To emphasize the features of this new specific and competitive 
strategy for restoring the angiogenic balance in preeclampsia, 
we compared the performances of the proposed approach with 
the specific strategy based on the use of antibodies for the cap-
ture of sFlt-1. Magnetic beads were functionalized either with 
VEGF or with anti–sFlt-1 antibody in a similar range of ligand 
surface density. Their performances in restoring the angiogenic 
balance in complex media (cell culture supernatants and mixed 
plasma of pregnant women) were compared using an equivalent 
amount of beads during the incubation. In Figure 3, we see that 
both systems capture sFlt-1 in the same range. However, the 
competitive approach, by releasing PlGF, is more efficient for 
the final objective of restoring the angiogenic balance.
It should also be mentioned that both systems suffer a loss 
of efficiency in the capture of sFlt-1 when the sample matrix 
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is more complex. Thus, antibody anti-sFlt-1 grafted beads cap-
ture 37% of sFlt-1 in CM and 23% in plasma, whereas V-beads 
capture 51% in CM and 15% in plasma capture. This fact could 
be explained by the complexification of the sample matrix.
Optimization of the Microfluidic Conditions
To test this approach in a dynamic setting, a microfluidic 
polydimethylsiloxane chip of the magnetic fluidized bed pre-
viously described10 was used to increase the surface-to-volume 
Figure 1. Proof of concept of the specific and competitive apheresis approach using recombinant proteins in physiological buffer medium (PBS at pH 7.4). A, 
Schematic representation of the rhVEGFR1/Fc/rhPlGF (recombinant human sFlt-1 with an antibody constant fraction) complex formation and its interaction 
with VEGF (vascular endothelial growth factor)-coated beads (V-beads), showing the hypothesis of our work (the ability to displace the PlGF complexed to 
sFlt-1); B, Evolution of the concentration of rhsFlt-1 after being incubated with V-beads; C, Evolution of the concentration of rhPlGF after incubation with 
V-beads. Please note that in B and C, i, C1, C2, and C3 are 3 solutions of complexes with different initial concentrations of rhVEGFR1/Fc (ie, 52.3; 43.7; 
and 29.2 pmol/L, respectively); obtained after 1 h incubation at 37°C of rhVEGFR1/Fc in PBS/0.1% BSA to the same volume of 4 ng/mL rhPlGF solution 
in PBS/0.1% BSA. Complex formation was quantified after assay of free rhPlGF with Quantikine kits. B and C, ii, Two hundred microliters of the solution 
of rhVEGFR1/Fc/rhPlGF complexes was incubated with 5 µL (50 µg) of V-beads at 105 pmol of bt-VEGF (biotinylated VEGF)/mg beads. Nonfunctionalized 
beads (C-beads) were used for negative control; concentrations of free rhPlGF and rhVEGFR1/Fc were measured with Quantikine kits. Sample denotes initial 
rhVEGFR1/Fc/rhPlGF formed complexes. rhsFlt-1 indicates recombinant human sFlt-1. *P<0.001.
Figure 2. Impact of the grafting rates of VEGF (vascular endothelial growth factor)-coated beads (V-beads) on their capture/release performances in 
conditioned media (CM) of human trophoblastic cells. The amount of bt-VEGF (biotinylated VEGF) coated on streptavidin Dynabeads was evaluated from 30 
to 259 pmol/mg of beads corresponding to a surface ligand density ranging from 11.7·103 to 102·103 VEGF/µm2. Grafting of V-beads is done following the 
protocol in Bouzas-Ramos et al.13 A, sFlt-1 capture and (B) PlGF (placental growth factor) release after 2.5-h incubation at 37ºC with stirring. Note that the 
marked excess is the molar excess of VEGF compared with the initial concentration of sFlt-1.
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interactions during the treatment of the CM and the plasma 
samples with the functionalized beads. Here, the solid phase 
of V-beads is continuously recirculated (fluidization) during 
the percolation of a liquid phase (the biological samples). In 
the following sections, we present the different steps of the 
optimization of the microfluidic device-based approach.
Time of Residence of the Sample Inside the Bed
We assessed the impact of the sample residence time inside 
the bed of magnetic beads. This residence time is directly 
correlated with the flow rate and the bed porosity. We used a 
CM of primary human trophoblastic cells where concentra-
tions of sFlt-1 and PlGF were, respectively, 0.26 and 0.013 
pmol/mL. Experiments with 150 µL of biological samples 
were performed at a flow rate ranging from 0.5 µL/min (res-
idence time of 7.7 s) to 3 µL/min (residence time of 2.9 
s). As shown in Figure 4A, increasing the residence time 
of each molecule inside the chip improved the capture of 
sFlt-1 and the release of PlGF in a nonlinear way because 
the optimum capture/release mechanism was reached at 6.5 
s of residence time, representing a flow rate of 1 µL/min 
and a total experiment time of 2.5 hours. This residence 
time is in agreement with the results obtained in static con-
ditions (Figure S4). As shown in Figure 4B, 6.5 s of resi-
dence time is enough to reach a final sFlt-1/PlGF ratio at 
a physiological level below 38 for a sample with an initial 
ratio around 80. Indeed, Zeisler et al15 identified an sFlt-1/
PlGF ratio cutoff of 38 as having important predictive value 
in clinical practice.
For the following experiments, a flow rate of 1 µL/min 
was chosen to percolate the sample through the bed, which 
means a residence time of 6.5 s of the biological sample inside 
the chip. When the experiment was performed with C-beads 
(the abscissa 0 in Figure 4), no capture and no release could 
be measured and the sFlt-1/PlGF ratio was not affected by the 
sample percolation through the bed of beads.
Surface Ligand Density of the Beads
The performance of capture/release of sFlt-1/PlGF in the 
microfluidic device was evaluated considering the surface 
ligand density of the magnetic beads. The amount of bt-
VEGF coated on streptavidin Dynabeads was evaluated as 
11.7·103 to 158·103 VEGF/µm2. We showed that increasing 
the VEGF surface density on the beads from 11.7 to 41.0·103 
VEGF/µm2 beads increased the capture of sFlt-1. However, 
large ligand surface densities induced a decrease of cap-
ture of sFlt-1 (Figure S5). Thus, 41.0·103 VEGF/µm2 was 
the final surface ligand density selected for the experiments. 
These findings are in agreement with the static experiments 
(Figure 2).
Figure 3. Comparison of specific systems to restore the angiogenic balance, one based on anti–sFlt-1 antibodies grafted beads (Ab-beads) and the other 
on competitive ligand (VEGF [vascular endothelial growth factor]) grafted beads (V-beads) in complex media. A, Schematic representation of the antibody-
grafted beads during the capture of sFlt-1. B, Capture/release performances of both specific systems in conditioned media (CM); C, Capture/release 
performances of both specific systems in plasma. Note: The beads were grafted at 105 pmol VEGF and 25 pmol anti–sFlt-1 Ab per mg of beads ensuring 
an excess of biomolecule respect to the initial amount of sFlt-1 in the sample of 98× and 23×, respectively, in the case of CM; and 890- and 212-fold, 
respectively, in the case of the pooled plasma. (CM: 265 pg/mL PlGF (placental growth factor); 20 692 pg/mL sFlt-1. Pooled plasma: 502 pg/mL PlGF; 2250 
pg/mL sFlt-1). bt indicates biotinylated; rhPlGF, recombinant human PlGF; and rhsFlt-1, recombinant human sFlt-1.
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Validation of the Approach in Complex Matrices: 
From Cell Culture to Human Plasma
To validate our system, we used 2 types of biological samples, 
CM of human trophoblastic cells (n=3) and plasma from preg-
nant women with preeclampsia (n=3). The details on these 
samples are summarized in Table S3.
First, we tested our device with CM from human primary 
trophoblastic cells. For each of the samples tested, we were 
able to capture sFlt-1, release PlGF and consequently decrease 
the sFlt-1/PlGF ratio. As shown in Figure 5A, we captured 
>70% of the sFlt-1 of the sample and released half to more 
than double the initial quantity of PlGF. The final sFlt-1/PlGF 
ratio in CM was significantly reduced and systematically 
below the physiological level of 38 (Figure 5C).
Finally, with plasma samples from pregnant women with 
preeclampsia (Figure 5B), we observed a ≈40% reduction of 
sFlt-1 and an increase in free PlGF concentration from one-
sixth to more than double in all the tested samples. Thus, our 
microfluidic system with V-beads decreased the sFlt-1/PlGF 
ratio in plasma samples by 63% on average (Figure 5D).
We also assessed the potential release of VEGF after sFlt-1 
apheresis. Free VEGF was almost undetectable in our samples 
(CM and maternal plasma) and systematically increased after 
incubation with V-beads (Figure S6). In addition, because 
sVEGFR-2 is detectable in plasma samples from pregnant 
women, but not in CM, we evaluated the ability of our V-beads 
to trap some sVEGFR-2. After incubation of plasma samples 
with V-beads, depletion in sFlt-1 and sVEGFR-2 was observed, 
showing that beads are also able to capture sVEGFR-2 signifi-
cantly (Figure S7). Note that the initial concentrations of both 
receptors are in the same range. However, in all cases sFlt-1 
were preferentially captured (23±5% for sFlt-1 versus 12±5% 
for sVEGFR-2, mean values).
Discussion
Extracorporeal strategies to treat preeclampsia are evaluated 
for 3 main reasons:1 the suspected primary role of circu-
lating sFlt-1 in the pathogenesis of the disease,2 the develop-
ment of drugs that act specifically on the soluble form and 
not on the membrane form is particularly complex, and3 
apheresis methods avoid the adverse effects of molecules 
that cross the placenta. We decided to target sFlt-1 because 
of mounting evidence of its involvement in the pathogenesis 
of preeclampsia.16–19 Soluble Flt-1 has been postulated to exert 
inhibitory effects on angiogenic signaling via 2 mechanisms: 
direct sequestration of angiogenic ligands, such as VEGF and 
PlGF and dominant-negative heterodimerization with surface 
VEGFRs.20
In vivo, the angiogenic effects are mainly related to 
the binding of VEGF to VEGFR-2. PlGF does not bind to 
VEGFR-2, but regulates VEGF bioavailability for VEGFR-2 
by competing with VEGF-A in binding to VEGFR-1.21 PlGF 
may also have direct angiogenic activity via intracellular sig-
naling triggered by its binding to the VEGFR-1 membrane 
receptor.22 During normal pregnancy, massive amounts of 
PlGF are produced by the placenta, reaching concentra-
tions of free PlGF around 400 pg/mL, whereas during pre-
eclampsia, free PlGF is extremely low due to the release 
of sFlt-1 into the maternal circulation.23 Our sFlt-1 capture 
strategy consists of a specific and competitive approach 
Figure 4. Evolution of concentrations of sFlt-1 
and PlGF (placental growth factor) as a function 
of the residence time of each molecule inside the 
matrix (50 µg) of magnetic beads (beads ligand 
density: 41·103 VEGF (vascular endothelial growth 
factor)/µm2; 105 pmol VEGF/mg beads) in the 
microfluidic device. A, the capture of sFlt-1 and 
the release of free PlGF and (B) the comparison 
between the initial and final sFlt-1/PlGF ratio. 
The abscissa 0 represents a control experiment 
done with Streptavidin Dynabeads M-280 
without coating. Evolution of the concentration of 
molecules was evaluated as delta=
C C
C
fin init
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where concentrations are measured in pmol/mL. 
*P<0.001.
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between the VEGF coated on the beads and the PlGF bound 
to the sFlt-1. The decline in total sFlt-1 is, therefore, as im-
portant as the increase in free PlGF for our study end point, 
which is why we used the sFlt-1/PlGF ratio for the expres-
sion of our results. To capture sFlt-1 in vitro in static and 
dynamic conditions, we used streptavidin magnetic beads, 
which are easy to functionalize with specific ligands (eg, 
biotinylated VEGF, Figure S2). Before application, we per-
formed several tests to evaluate surface ligand density (Table 
S1) and the ability to recognize sFlt-1 by the grafted ligand 
(Figure S2), as well as the storage stability of the V-beads 
(up to 2 weeks at 4°C, Figure S8). Then, the sFlt-1 capture 
combined with PlGF release was proven mainly by 2 series 
of experiments. First, with the rhVEGFR1/Fc/rhPlGF com-
plexes in static conditions, we checked the total amount of 
PlGF used in the experiments, which is not possible with 
more complex media (CM, plasma) because human PlGF 
ELISA kits only measure free PlGF. These experiments 
demonstrated the ability of V-beads to capture rhVEGFR1/
Fc and also to release rhPlGF significantly (20% of the initial 
complexed PlGF). Second, our approach was compared with 
another specific capture strategy based on beads coated with 
an sFlt-1 antibody. We demonstrated an equivalent capture 
rate of sFlt-1, but with the addition of increased free PlGF in 
solution, which proves the potential interest of our competi-
tive approach. The increase in free PlGF in solution after in-
cubation with the V-beads may be caused by the combination 
of 2 phenomena. The initially free sFlt-1 is trapped by the 
V-beads, resulting in a shift of the biochemical equilibrium 
towards free PlGF (see equilibrium equation in Figure 1A). 
In addition, the V-beads compete with the PlGF bound to the 
sFlt-1, and due to the excess VEGF used for the incubation, 
we can displace the bound PlGF (Figure 2 and Figure S5). 
Finally, maybe because of this large excess of VEGF grafted 
on the beads, our approach is also able to displace the bound 
VEGF. This release of VEGF is sample-dependent (Figure 
S6), which shows the complexity of the VEGFs/VEGFRs 
system and the importance of the biochemical equilibria. 
During normal pregnancy, circulating free VEGF levels are 
very low, almost undetectable with noncompetitive ELISA. 
Whether these extremely low levels of VEGF have a physi-
ological role during pregnancy is not known. Eremina et al24 
have shown that tight regulation of VEGF-A signaling is crit-
ical for establishment and maintenance of the glomerular fil-
tration barrier. A slight elevation of circulating endogenous 
free VEGF could be beneficial, especially for the glomerular 
dysfunction characterized by proteinuria and endotheliosis, 
the renal lesion seen in preeclampsia.
The second part of our work was performed under dynamic 
conditions. To mimic the dynamic binding and release on the 
solid phase that take place in extracorporeal circulation and 
to evaluate the potential of our approach, we used the micro-
fluidic fluidized bed model. The microfluidized bed allows 
the use of the same magnetic beads as for the static condi-
tions while limiting the consumption of samples and reagents. 
Moreover, the magnetic fluidized bed has many advantages 
in applications involving fluid-solid exchanges, such as high 
surface-to-volume ratio, constant mixing, and low flow resist-
ance.10 Our results demonstrate the proof of concept of signifi-
cant sFlt-1 capture combined with the release of PlGF in these 
Figure 5 . Performance of sFlt-1 capture and PlGF (placental growth factor) release in conditioned media (CM) from human trophoblastic primary cell culture 
(A) and human plasma from preeclamptic (PE) women (B) after passage through the microfluidic device at the optimized conditions (1 μL/min, 37°C). Evolution 
of the sFlt-1/PlGF ratio CM (C) and plasma samples (D) after passage through the microfluidic device at the same conditions. Beads ligand density: 41·103 
VEGF (vascular endothelial growth factor)/um2 (105 pmol VEGF/mg beads). Performances are evaluated as delta=
C C
C
fin init
init
[ ] −
[ ]
[ ]
 with concentrations measured 
in pmol/mL. *P<0.001.
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dynamic conditions, with a 68% reduction of sFlt-1/PlGF 
ratio in plasma from preeclamptic women. The flow rates and 
the fluid volumes are low in such conditions and not compat-
ible with application in pregnant women (50–60 mL/min),6 
but this dynamic microscale technique is of value in testing 
different molecules in the capture of sFlt-1 in preeclamptic 
plasma because of the limited amount of human material. This 
microfluidic device could also be of interest for a proof of con-
cept of this approach in animal models.
Using VEGF as a competitive ligand for capture of sFlt-1 
and release of PlGF, not only sFlt-1 is captured in the plasma 
of preeclamptic women but also sVEGFR-2 (Figure S7). The 
physiological impact of sVEGFR-2 in normal and patho-
logical pregnancies is unclear. Mothers destined to develop 
preeclampsia have lower plasma sVEGFR-2 concentrations 
than those who have a normal pregnancy.25 Work is currently 
underway to develop ligands with an affinity that is both 
greater than that of PlGF for sFlt-1 and significantly lower for 
sVEGFR-2 than for sFlt-1.
Perspectives
The nest steps of our strategy are: (1) to optimize the grafting 
with a VEGF-like molecular ligand, specific for sFlt-1, allowing 
no binding of sKDR; (2) to evaluate the biological effects of the 
release in the maternal circulation of the endogenous VEGF; 
and (3) to develop apheresis columns based on our ligand-
based approach and usable in vivo with an animal model.
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What Is New
•	Our work provides proof of concept of a new strategy to capture cir-
culating sFlt-1 and release endogenous PlGF (placental growth factor). 
This approach is based on a competitive and biomimetic strategy to bind 
sFlt-1 with its natural ligand (VEGF [vascular endothelial growth factor]) 
and release part of the PlGF trapped by sFlt-1.
What Is Relevant?
•	This technique rebalances the sFlt-1/PlGF ratio in the maternal plasma, 
offering new perspectives for the treatment of preeclampsia.
Novelty and Significance
